Skip to main content
SpringerLink
Log in

Impact of Gene Variability on Drug Metabolism

  • Chapter
Drug Metabolism

  • 1922 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ritter JM. 1999. Pharmacogenetics. In: Ritter JM, Lewis LD, Mant TGK, editors. A Textbook of Clinical Pharmacology, 4th ed. London: Arnold (publisher)-member of the Hodder Headline Group, pp 108–118.

    Google Scholar 

  2. Linder MW, Prough RA, Valdes R Jr. 1997. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 43:254–266.

    PubMed  CAS  Google Scholar 

  3. Meyer UA. 2000. Pharmacogenetics. In: Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW, editors. Melmon and Morrelli’s Clinical Pharmacology: Basic Priciples in Therapeutics, 4th ed. New York: McGraw-Hill Medical Publishing Division, pp 1179–1205.

    Google Scholar 

  4. Bechtel P, Bechtel Y. 2000. Pharmacogenetics of biotransformations. In: Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW, editors. Clinical Pharmacology. Basic Principles in Therapeutics, 4th ed. New-York: McGraw-Hill Medical Publishing Division, pp 25–36.

    Google Scholar 

  5. Tischio JP. 2000. Pharmacogenetics. In: Gennaro AR editor. Remington’s: The Science and Practice of Pharmacy, 20th ed. Philadelphia: College of Pharmacy and Science, pp 1169–1173.

    Google Scholar 

  6. Dally AK. 1999. Pharmacogenetics, In: Woolf TF, editor. Handbook of Drug Metabolism. London: Marcel Dekker Inc., pp 175–189.

    Google Scholar 

  7. Vogel F. 1959. Moderne Probleme der Humangenetik. Ergebn Inn Med Kinderheilkd 12:52.

    Google Scholar 

  8. Rostami-Hodjegan A, Ticker G. 2004. ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug-drug interactions. Drug Discov Today: Technologies 1:441–448.

    Article  CAS  Google Scholar 

  9. Desai VG, Moland CL, Branham WS, Delongchamp RR, Fang H, Duffy PH, Peterson CA, Beggs ML, Fuscoe JC. 2004. Changes in expression level of genes as a function of time of day in the liver of the rats. Mutation Res 549:115–129.

    PubMed  CAS  Google Scholar 

  10. Thompson MA, Weinshilboum RM, El Yazal J, Wood TC, Pang Y-P. 2001. Rabbit indolethylamine N-methyltransferase three-dimensional structure prediction: a model approach to bridge sequence to function in pharmacogenomic studies. J Mol Model 7:324–333.

    Article  CAS  Google Scholar 

  11. Gonzales FJ, Idle JR. 1994. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet 26:59–67.

    Google Scholar 

  12. Daly AK, Cholerton S, Armstrong M, Idle JR. 1994. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 102:55–69.

    PubMed  Google Scholar 

  13. Poulsen HE, Loft S. 1994. The impact of genetic polymorphisms in risk assessment of drugs. Arch Toxicol 16:211–222.

    CAS  Google Scholar 

  14. Smith G, Stanley LA, Sim E, Strange RC, Woolf CR. 1995. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 25:27–34.

    PubMed  CAS  Google Scholar 

  15. Kapur G, Mattoo T, Aranda JV. 2004. Pharmacogenomics and renal drug disposition in newborn. Seminars in Perinatology 28:132–140.

    Article  PubMed  Google Scholar 

  16. Moerike K, Schwab M. 2003. The cytochrome-P450 enzyme system and its role in drug metabolism. Interaktionen und Wirkmechanismen Ausgewaehlter Psychopharmaka (2nd ed), pp 4–18.

    Google Scholar 

  17. Golstein JA, de Morais SMF. 1994. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285–292.

    Google Scholar 

  18. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T. 2004. Cyp2d6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants — a pilot study. Clin Pharmacol Ther 75:386–393.

    Article  PubMed  CAS  Google Scholar 

  19. Bertilsson L. 1995. Geographical/Interracial Differences in Polymorphic Drug Oxidation. Current State of Knowledge of Cytochromes P450 (CYP)2D6 and 2C19. Clin Pharmacokinet 29:192–209.

    PubMed  CAS  Google Scholar 

  20. Johansson I, Yue QY, Dahl ML, Heim M, Saewe J, Betilsson L, Meyer UA, Sjoeqviat F, Ingelman-Sundberg M. 1991. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 40:553–556.

    PubMed  CAS  Google Scholar 

  21. Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS. 1993. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 91:2150–2154.

    Article  PubMed  CAS  Google Scholar 

  22. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. 1995. Ultra rapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516–520.

    PubMed  CAS  Google Scholar 

  23. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. 2004. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50:195–200.

    Article  PubMed  CAS  Google Scholar 

  24. Ingelman-Sundberg M. 2002. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 181–182:447–452.

    Article  PubMed  Google Scholar 

  25. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. 2003. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 74:134–137.

    Article  CAS  Google Scholar 

  26. Richter T, Schwab M, Eichelbaum M, Zanger UM. 2005. Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem Pharmacol 69:517–524.

    Article  PubMed  CAS  Google Scholar 

  27. Kupfer A, Presig R. 1984. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753–759.

    Article  PubMed  CAS  Google Scholar 

  28. Ward SA, Goto F, Nakamura K, Jacqz E, Wilkinson GR, Branch RA. 1987. S-mephenytoin 4-hydroxylase is inherited as an autosomal recessive trait in Japanese families. Clin Pharmacol Ther 42:96–99.

    Article  PubMed  CAS  Google Scholar 

  29. Masimirembwa C, Bertilsson L, Johnansson I, Hasler JA, Ingelman-Sundberg M. 1995. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 57: 656–661.

    Article  PubMed  CAS  Google Scholar 

  30. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. 1985. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402–408.

    Article  PubMed  CAS  Google Scholar 

  31. De Morais SMF, Wilkinson GR, Blaidsdell J, Nakamura K, Meyer UA, Goldstein JA. 1994. The major genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in humans. J Biol Chem 269:1541–1549.

    Google Scholar 

  32. Anersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L. 1990. Slow omeprazole metabolisers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12:48–62.

    Google Scholar 

  33. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. 1989. Propranolol’s metabolism is determined both by mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 45:72–79.

    Article  PubMed  CAS  Google Scholar 

  34. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. 1989. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348–355.

    Article  PubMed  CAS  Google Scholar 

  35. Rost K, Brosicke H, Brockmoller J, Scheffler M, Helge H, Roots I. 1992. Increase of cytochrome P450 1A2 activity by omeprazole: Evidence by the 13C[N-3-methyl]-caffeine breath test in poor metabolisers of S-mephenytoin”, Clin Pharmacol Ther 52:170–181.

    Article  PubMed  CAS  Google Scholar 

  36. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenbrige Am. 1991. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation phenotype — a panel study. Br J Clin Pharmacol 31:689–692.

    PubMed  CAS  Google Scholar 

  37. Horsmans Y, Lannes, Pessayre D, Larrey D. 1994. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J Hepatol 21:1075–1079.

    Article  PubMed  CAS  Google Scholar 

  38. Zhou HL, Anthony LB, Wood AJJ, Wilkinson GR. 1990. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 30:471–475.

    PubMed  CAS  Google Scholar 

  39. Flockhart DA. 1995. Drug interactions and the cytochrome P450 system: the role of cytochrome P450 2C19. Clin Pharmacokinet 29:45–51.

    PubMed  CAS  Google Scholar 

  40. Daly AK, Cholerton S, Gregory W, Idle JR. 1993 Metabolic polymorphisms. Pharmacol Ther 57:129–141.

    Article  PubMed  CAS  Google Scholar 

  41. Wang S-L, Huang J-D, Lai M-d, Tsai J-J. 1995. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37–45.

    PubMed  CAS  Google Scholar 

  42. Guengerich FT, Kim D-H, Iwasaki M. 1991. Role of cytochrome P450 2E1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol, 4:168–179.

    Article  PubMed  CAS  Google Scholar 

  43. Raucy JL, Lasker JM, Lieber KS, Black M. 1989. Acetaminophen activation by human liver cytochromes 450 2E1. Arch Biochem Biophys 271:270–283.

    Article  PubMed  CAS  Google Scholar 

  44. Pattern CJ, Thomas PE, Guy RL, Lee M, Gonzales FJ, Guengerich FP, Yang CS. 1993. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 6:511–518.

    Article  Google Scholar 

  45. Umeno M, McBride W, Yang CS, Gelboin HV, Gonzales FJ. 1988. Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 27:9006–9013.

    Article  PubMed  CAS  Google Scholar 

  46. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R, Watanabe M. 1991. Association between restriction fragment length polymorphism of the human cytochrome P450IIe1 gene and susceptibility to lung cancer. Jpn J Cancer Res 82:254–256.

    PubMed  CAS  Google Scholar 

  47. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP. 1990. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem Res Toxicol 3:566–573.

    Article  PubMed  CAS  Google Scholar 

  48. Kim RB, O’Shea, Wilkinson GR. 1995. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 57:645–655.

    Article  PubMed  CAS  Google Scholar 

  49. Watanabe J, Hayashi S-I, Nakachi K, Imai K, Suda Y, Sekine T. 1990. Pstl and Rsal RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res 18:7194.

    PubMed  CAS  Google Scholar 

  50. Watkins PB. 1994. Non-invasive tests of CYP3A enzymes. Pharmacogenetics 4:171–183.

    PubMed  CAS  Google Scholar 

  51. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T. 1995. Cytochrome P450hPCN3, a novel cytochrome P450 IIA gene product that is differentially expressed in adult human liver. J Biol Chem 264:10388–10395.

    Google Scholar 

  52. McKinnon RA, Burgess WM, Hall P de la M, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. 1995. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36:259–267.

    PubMed  CAS  Google Scholar 

  53. Daly AK. 1999. Pharmacogenetics. In: Woolf TF, editor. Handbook of Drug Metabolism. New York, Marcel Dekker Inc., pp175–202.

    Google Scholar 

  54. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. 2004. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects on liver function. Clin Pharmacol Ther 75:80–88.

    Article  PubMed  CAS  Google Scholar 

  55. Peterson TC, Peterson MR, Wornell PA, Blanchard MG, Gonzalez FJ. 2004. Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction. Biochem Pharmacol 68:395–402.

    Article  PubMed  CAS  Google Scholar 

  56. Humbert R, Adler DA, Disteche DM, Hasset C, Omiecinski CJ,. Furlong CF. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 3:73–77.

    Article  PubMed  CAS  Google Scholar 

  57. Lockridge O. 1990. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther 47:35–39.

    Article  PubMed  CAS  Google Scholar 

  58. Mackness B, Durrington PN, Mackness MI. 1998. Human Serum Paraoxonase. Gen Pharmac 31:329–336.

    Article  CAS  Google Scholar 

  59. Oesch F, Timms CW, Waker CH, Guenthner TM, Sparrow A, Watabe T. 1994. Existence of multiple forms of microsomal epoxide hydrolases with radically different substrate specificities. Carcinogenesis 5:7–11.

    Google Scholar 

  60. Kalsotra A, Turman CM, Kikuta Y, Strobel HW. 2004. Expression and characterisation of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol 199:295–304.

    Article  PubMed  CAS  Google Scholar 

  61. Patel M, Tang BK, Kalow W. 1993. Variability of acetaminophen metabolism in Caucasians and Orientals. Pharmacogenetics 2:38–43.

    Google Scholar 

  62. Furuta S, Kamada E, Omata T, Sugimoto T, Kawabata Y, Yonezawa K, Wu XC, Kutimoto T. 2004. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT 1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol 497:223–231.

    Article  PubMed  CAS  Google Scholar 

  63. Weinshilboum R. 1990. Sulphotransferase pharmacogenetics. Pharmacol Ther 45:93–99.

    Article  PubMed  CAS  Google Scholar 

  64. Her C, Raftogianis R, Weinshilboum RM. 1996. Human phenol sulphotransferase STP2 gene: Molecular cloning, structural characterisation, and chromosomal location. Genomics 33:409–416.

    Article  PubMed  CAS  Google Scholar 

  65. Bernier F, Soucy P, Luu-The V. 1996. Human phenol sulphotransferase gene contains two alternative promoters: Structure and expression of gene. DNA Cell Biol 15:367–376.

    PubMed  CAS  Google Scholar 

  66. Evans DAP. 1960. Genetic control of isoniazid metabolism in man. Br Med J 2:485–491.

    Article  PubMed  CAS  Google Scholar 

  67. Liu HJ, Han C-Y, Lin KB, Bruce K, Hardy S. 1994. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4:125–134.

    Google Scholar 

  68. Smith MT, Evans CG, Doane-Setzer P, Castro VM, Tahir MK, Mannervik B. 1989. Denitrosation of 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) by class m glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res 49:2621–2627.

    PubMed  CAS  Google Scholar 

  69. Evans CG, Bodell WJ, Ross D, Doane P, Smith MT. 1986. Role of glutathione and related enzymes in brain tumor resistance to BCNU and nitrogen mustard. Proc Am Assoc Cancer Res 37:267–274.

    Google Scholar 

  70. Weinshilboum R, Sladek SL. 1990. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651–658.

    Google Scholar 

  71. Funck-Brentano C, Becquemont L, Kroemer HK, Buhl K, Knebel NG, Eichelbaum M, Jaillon P. 1994. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 55:256–269.

    Article  PubMed  CAS  Google Scholar 

  72. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. 1991. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochem 30:3247–3253.

    Article  CAS  Google Scholar 

  73. Scott J, Poffenbarger PL. 1979. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 28:41–46.

    PubMed  CAS  Google Scholar 

  74. Devadatta S, Gangadharam PR, Andrews RH, Fox W, Ramakrishnan CV, Selkon JB, Velu S. 1960. Peripheral neuritis due to isoniazid. Bull WHO 23:587–598.

    PubMed  CAS  Google Scholar 

  75. Kutt H, Brennan R, Dehejia H, Verebely K. 1970. Diphenylhydantoin intoxication: a complication of isoniazid therapy. Am Rev Respir Dis 101:377–384.

    PubMed  CAS  Google Scholar 

  76. Mackness B, Durrington PN, Mackness MI. 1998. Human serum paraoxonase. Gen Pharmacol 31:329–336.

    Article  PubMed  CAS  Google Scholar 

  77. Hiroyuki O. 2002. Pharmaco informatics. Farumashia 38:120–124.

    Google Scholar 

Download references

Editor information

Editors and Affiliations

  1. “I. Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

    Corina Ionescu

  2. University of Cape Town, South Africa

    Mino R. Caira

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer

About this chapter

Cite this chapter

(2005). Impact of Gene Variability on Drug Metabolism. In: Ionescu, C., Caira, M.R. (eds) Drug Metabolism. Springer, Dordrecht. https://doi.org/10.1007/1-4020-4142-X_7

Download citation

Publish with us

Policies and ethics

Search

Navigation